Administration of β-carotene (20, 40 and 60 mg/kg) dose-dependently significantly decreased blood ALT, AST and ALP activities in β-carotene-treated groups (p < 0.01) compared to untreated HCC rats. Here, GPT is linked to hepatocellular carcinoma.